Cidara Therapeutics

Cidara Therapeutics, Inc. is a biotechnology company, which engages in the discovery, development, and commercialization of novel anti-infectives. Its product pipeline includes Rezafungin and Cloudbreak. The company was founded by Kevin M. Forrest, Kevin J. Judice, and H. Shaw Warren in December 2012 and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Cidara Therapeutics, Inc. is a biotechnology company, which engages in the discovery, development, and commercialization of therapeutics for patients facing serious diseases, specifically oncology and infectious diseases. Its product pipeline includes Rezafungin Acetate and Cloudbreak. The company was founded by Kevin M. Forrest, Kevin J. Judice, and H. Shaw Warren in December 2012 and is headquartered in San Diego, CA.

Financing led by new investor, Venrock Healthcare Capital Partners, with significant participation by new and existing life sciences-focused investors Financing led by new investor, Venrock Healthcare Capital Partners, with significant participation by new and existing life sciences-focused investors

Cidara Therapeutics Announces $105 Million Private Placement

SAN DIEGO, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, today announced that Jeffrey Stein, Ph.D., President and Chief Executive Officer, will participate in the Evercore 7th Annual HealthCONx Conference.

Cidara Therapeutics to Participate in Evercore 7th Annual HealthCONx Conference

SAN DIEGO, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX) (the Company), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, today reported financial results for the third quarter ended September 30, 2024, and provided an update on its corporate activities and product pipeline.

Cidara Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results

SAN DIEGO, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, today announced that Jeffrey Stein, Ph.D., President and Chief Executive Officer, will participate in the following November investor conferences.

Cidara Therapeutics to Participate in Two Upcoming November Investor Conferences

SAN DIEGO, Oct. 04, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, today announced that the Compensation Committee of its Board of Directors (Compensation Committee) granted Dipesh Bhatt, a new employee, a non-qualified stock option award and restricted stock units (RSUs) for an aggregate of 1,110 shares of its common stock, pursuant to the Cidara Therapeutics, Inc. 2020 Inducement Incentive Plan, as amended (the Inducement Plan), with a grant date of September 30, 2024. The stock option has an exercise price of $10.75 per share, which is equal to the closing price of Cidara's common stock on the grant date. The shares subject to the option will vest over four years, with 25% of the shares vesting on the one-year anniversary of the vesting commencement date and the balance of the shares vesting in a series of 36 successive equal monthly installments thereafter. All RSUs vest in four equal annual installments, with 1/4 vesting on each of the first, second, third and fourth anniversaries of the Quarterly Vesting Date (as defined below) that occurs during the calendar quarter that includes the date of grant. “Quarterly Vesting Date” means March 10, June 10, September 10 or December 10. The awards are subject to the award holder's continuous service through each vesting date and to the terms and conditions of the Inducement Plan and the standard forms of grant agreements thereunder.

Cidara Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)

SAN DIEGO, Sept. 25, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, today announced two presentations at OPTIONS XII for the Control of Influenza conference, to be held September 29 through October 2, 2024 in Brisbane, Australia. The presentations, one oral and one poster, will highlight safety and pharmacokinetic (PK) data from clinical studies of CD388, Cidara's influenza drug-Fc conjugate (DFC) candidate.

Cidara Therapeutics Announces Two Presentations on Innovative Drug-Fc Conjugate, CD388, at the 2024 OPTIONS XII for the Control of Influenza Conference

The Phase 2b trial will enroll 5,000 subjects across clinical sites in the US and UK The Phase 2b trial will enroll 5,000 subjects across clinical sites in the US and UK

Cidara Therapeutics Announces First Subjects Dosed in Phase 2b NAVIGATE Trial Evaluating CD388 for the Prevention of Seasonal Influenza

SAN DIEGO, Sept. 19, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, today announced the appointment of Rick Bright, Ph.D., Philip Krause, M.D., Mario Barro, Ph.D., and Frederick G. Hayden, M.D., FACP to its Scientific Advisory Board (SAB).

Cidara Therapeutics Strengthens its Scientific Advisory Board with Infectious Disease Experts

SAN DIEGO, Sept. 12, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, today announced a reduction in its workforce to focus on the clinical development of CD388, the Company's novel DFC candidate for influenza A and B. The planned reduction impacts approximately 30% of the Cidara workforce.

Cidara Therapeutics Restructures Workforce to Focus on Planned Clinical Development of CD388

SAN DIEGO, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX) (the Company), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, today announced that Jeffrey Stein, Ph.D., President and Chief Executive Officer, will present at the H.C. Wainwright 26th Annual Global Investment Conference.

Cidara to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Appointment adds biotech veteran with over two decades of business development, strategy, and operational experience to Cidara's management team Appointment adds biotech veteran with over two decades of business development, strategy, and operational experience to Cidara's management team

Cidara Therapeutics Announces Appointment of Jim Beitel as Chief Business Officer

SAN DIEGO, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX) (the Company), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, today reported financial results for the second quarter ended June 30, 2024, and provided an update on its corporate activities and product pipeline.

Cidara Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results

SAN DIEGO, July 03, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, today announced that the Compensation Committee of its Board of Directors granted Corrina Pavetto, a new employee, a non-qualified stock option award and restricted stock units (RSUs) for an aggregate of 10,275 shares of its common stock, pursuant to the Cidara Therapeutics, Inc. 2020 Inducement Incentive Plan, with a grant date of June 28, 2024. The stock option has an exercise price of $11.94 per share, which is equal to the closing price of Cidara's common stock on the grant date. The shares subject to the option will vest over four years, with 25% of the shares vesting on the one-year anniversary of the vesting commencement date and the balance of the shares vesting in a series of 36 successive equal monthly installments thereafter. All RSUs vest in four equal annual installments, with 1/4 vesting on each of the first, second, third and fourth anniversaries of the Quarterly Vesting Date that occurs during the calendar quarter that includes the Date of Grant. Quarterly Vesting Date means March 10, June 10, September 10 or December 10. The awards are subject to the award holder's continuous service through each vesting date and to the terms and conditions of Cidara's 2020 Inducement Incentive Plan and its standard forms of grant agreements thereunder.

Cidara Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, May 30, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, today announced the company will be presenting a poster at the American Society for Microbiology (ASM) Microbe 2024 conference to be held June 13-17, 2024 at the Georgia World Congress Center in Atlanta, Georgia.

Cidara Therapeutics to Present Preclinical Data on CD388 at ASM Microbe 2024 Conference

SAN DIEGO, May 15, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX) (the Company), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, today reported financial results for the first quarter ended March 31, 2024, and provided an update on its corporate activities and product pipeline.

Cidara Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results

SAN DIEGO, May 15, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, today announced that on May 14, 2024 it received a letter from the Listing Qualifications Department staff (the Staff) of the Nasdaq Stock Market LLC (Nasdaq) notifying the Company that it has regained compliance with Nasdaq's requirements for continued listing. In addition, the Nasdaq Hearing Panel (the Panel) imposed a discretionary Panel monitor until May 14, 2025, such that if the Company fails to maintain compliance with any continued listing requirement during such period, the Staff will issue a delist determination letter and the Company will promptly schedule a new hearing before the Panel to address such noncompliance.

Cidara Therapeutics Regains Compliance with Nasdaq Continued Listing Rules

NEW YORK, May 10, 2024 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Cidara Therapeutics, Inc. (NASDAQ: CDTX) resulting from allegations that Cidara Therapeutics may have issued materially misleading business information to the investing public. SO WHAT: If you purchased Cidara Therapeutics securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

CDTX INVESTOR NOTICE: ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Cidara Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation - CDTX

Cidara Therapeutics, Inc. passed rezafungin rights to Mundipharma allowing reallocation of resources to the oncology Cloudbreak platform. Following a considerable private placement and re-acquisition of CD388 from Janssen, CDTX is well funded to start and complete a ph2b trial. Cidara Therapeutics no longer expects any milestone/royalty revenue but will be able to raise funds from a much stronger position following a positive ph2b trial for CD388.

Cidara Therapeutics: Now Well-Funded To Advance Its Cloudbreak Platform

SAN DIEGO, April 26, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, today announced two poster presentations highlighting data on CD388 at the 34th European Society of Clinical Microbiology and Infectious Diseases (ESCMID) conference, being held April 27-30, 2024 in Barcelona, Spain.

Cidara Therapeutics Announces Presentations Highlighting Phase 1 and Phase 2a Clinical Data on CD388 at ESCMID 2024

NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Cidara Therapeutics, Inc. (NASDAQ: CDTX) resulting from allegations that Cidara Therapeutics may have issued materially misleading business information to the investing public. SO WHAT: If you purchased Cidara Therapeutics securities you may be entitled to compensation without payment of any out of pocket fees or costs through.

CDTX LOSS ALERT: ROSEN, A LEADING LAW FIRM, Encourages Cidara Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation – CDTX

Shares of Cidara Therapeutics CDTX, +19.90% rose sharply after the company announced a reshuffling of its portfolio of drug candidates.

Cidara Therapeutics shares surge 30% after reacquiring flu treatment

- $240 million private placement financing led by RA Capital Management with significant participation by Bain Capital Life Sciences as well as BVF Partners and Canaan Partners to fund Phase 2b clinical trial

Cidara Therapeutics Reacquires Global Development and Commercial Rights to CD388 and Announces Private Placement Financing of $240 Million

SAN DIEGO, April 24, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, today announced that it has entered into an asset purchase agreement with its current partner, Mundipharma*, for the divestiture of rezafungin. Mundipharma currently has commercial rights to rezafungin outside the U.S. and Japan. Mundipharma purchased the assets in consideration of its assumption of the ongoing obligation to conduct and fund the ReSPECT Phase 3 clinical trial, the costs of the rezafungin patent portfolio and CMC and regulatory obligations. Cidara estimates that it will achieve approximately $128 million in cost savings over the patent life of rezafungin comprised of approximately $67 million in clinical development expense, including the cost of the potential upsizing of the ReSPECT trial and CMC costs over the next three years, and an additional approximately $61 million in forecasted obligations through the expected patent life of rezafungin.

Cidara Therapeutics Announces Divestiture of Rezafungin to Mundipharma* to Focus on Advancing the Clinical Development of Cloudbreak DFC Pipeline

SAN DIEGO, April 22, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX) (the Company), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, today reported financial results for the fourth quarter and full year ended December 31, 2023 and provided an update on its corporate activities and product pipeline.

Cidara Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results

SAN DIEGO, April 22, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX) (the Company), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, announced on April 17, 2024, that the Company received a notice from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (Nasdaq) advising the Company that its failure to timely file its Annual Report on Form 10-K for the fiscal year ended December 31, 2023 (the Form 10-K) with the Securities and Exchange Commission (the SEC), in contravention of Nasdaq Listing Rule 5250(c)(1) (the Filing Requirement), could serve as an additional deficiency and basis for the delisting of the Company's securities from Nasdaq.

News for Cidara Therapeutics Stock (CDTX)